Moderna Inc.

Moderna will replace Warner Bros. Discovery in the NASDAQ 100 on October 9, a change made possible by the media group's merger and likely to trigger short‑term demand from index‑tracking investment products. The inclusion in the index is based on the higher market value after a strong price rally and increases visibility with passive and active funds, but does not change the company’s operations. A more durable price driver is the successful phase‑3 interim analysis of the mRNA cancer therapy Intismeran in combination with Merck’s Keytruda, although full data and approval are still pending. For investors the effect is mainly short‑term; in the long run clinical results and approval will determine the valuation, and BioNTech remains excluded for now. » More on finanzen.net

Moderna will be added to the Nasdaq 100 on Oct. 9 before trading begins, replacing Warner Bros. Discovery. The stock showed high intraday volatility but recovered significantly from its session low, despite a sell rating from Citi. Year to date the share price has more than sextupled, and market capitalization is around $75 billion. Warner Bros. Discovery is also being removed from other major indices amid the planned merger with Paramount Skydance. » More on deraktionaer.de

Moderna shares fell more than 5% after Citi judged the valuation unjustified following the sharp price rise and set a price target of $80. Citi analyst Geoff Meacham considers the expectations priced into the stock for expanding personalized cancer vaccines to many tumor types too high and arrives at roughly $100 per share in his discounted cash‑flow analysis. Even under very optimistic success assumptions, a share price around $200 would require annual cancer revenues of about $26 billion, meaning the analyst views the risk‑reward as tilted toward downside. The stock has already risen substantially since the Phase‑3 success of the cancer vaccine Intismeran against melanomas. » More on deraktionaer.de